Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H2, 2017

Date: August 30, 2017
Pages: 917
Price:
US$ 2,500.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: G595B448835EN
Leaflet:

Download PDF Leaflet

Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H2, 2017
Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H2, 2017

SUMMARY

GlobalData's clinical trial report, “Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H2, 2017' provides an overview of Glioblastoma Multiforme (GBM) clinical trials scenario. This report provides top line data relating to the clinical trials on Glioblastoma Multiforme (GBM). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

REASONS TO BUY
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Report Guidance
GlobalData Clinical Trials Report Coverage
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Five Countries Contributing to Clinical Trials in Middle East and Africa
Top Five Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Glioblastoma Multiforme (GBM)
Aug 22, 2017: GDC-0084 Progress Update: On Track for Phase II Commencement in 2017
Aug 22, 2017: Curtana Pharmaceuticals Successfully Completes Pre-IND Submission for CT-179 for the Treatment of Malignant Gliomas
Aug 08, 2017: Karyopharm Provides Update on Selinexor (KPT-330)
Jul 31, 2017: Diffusion Pharmaceuticals Selects Contract Research Organization for Phase 3 Clinical Trial of Lead Compound TSC for Inoperable GBM Brain Cancer
Jul 24, 2017: DelMar Pharmaceuticals Receives Approval from China's Human Genetic Resources Administration to Initiate Phase 2 Clinical Trial in Newly Diagnosed GBM
Jul 20, 2017: Diffusion Pharmaceuticals Achieves Drug Production Milestone For Planned Phase 3 Clinical Trial In Inoperable GBM Brain Cancer
Jul 18, 2017: DelMar Pharmaceuticals Announces Completion of First Site Initiation Visit for STAR-3 Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM
Jun 22, 2017: DelMar Pharmaceuticals Receives Institutional Review Board Approval for Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM
Jun 21, 2017: ImmunoCellular Therapeutics Provides Update on Strategic Review and Decision to Suspend Further Patient Randomization for ICT-107 Phase 3 Trial
Jun 05, 2017: MediciNova Announces Positive Results from a Glioblastoma Animal Model Study Presented at the 2017 American Society of Clinical Oncology Annual Meeting
Jun 05, 2017: Dr. Marnix Bosch To Present Update on DCVax-L at the ASCO Conference
Clinical Trial Profile Snapshots
Appendix
Abbreviations
Definitions
Research Methodology
Secondary Research
About GlobalData
Contact Us
Disclaimer
Source

LIST OF TABLES

Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Region, 2017*
Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, North America, Top Countries, 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017*
Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials, G7 Countries (%), 2017*
Glioblastoma Multiforme (GBM) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
Glioblastoma Multiforme (GBM) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials, E7 Countries (%), 2017*
Glioblastoma Multiforme (GBM) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*
Glioblastoma Multiforme (GBM) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Phase, 2017*
Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials In Progress by Phase 2017*
Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Trial Status, 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, by End Point Status, 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
Glioblastoma Multiforme (GBM) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*

LIST OF FIGURES

Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Region (%), 2017*
Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, North America, Top Countries (%), 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017*
Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials, G7 Countries (%), 2017*
Glioblastoma Multiforme (GBM) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
Glioblastoma Multiforme (GBM) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials, E7 Countries (%), 2017*
Glioblastoma Multiforme (GBM) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*
Glioblastoma Multiforme (GBM) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Phase (%), 2017*
Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017*
Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Trial Status, 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, by End Point Status, 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
Glioblastoma Multiforme (GBM) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*
GlobalData Methodology

COMPANIES MENTIONED

F. Hoffmann-La Roche Ltd
Merck & Co Inc
Pfizer Inc
Novartis AG
AstraZeneca Plc
Bristol-Myers Squibb Company
Eli Lilly and Company
Celgene Corp
Sarah Cannon Research Institute LLC
AbbVie Inc
Skip to top


Ask Your Question

Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H2, 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: